This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Osterziel, K. J. Articles by Dietz, R. Search for Related Content PubMed PubMed Citation Articles by Osterziel, K. J. Articles by Dietz, R.

The Severity of Chronic Heart Failure due to Coronary Artery Disease Predicts the Endocrine Effects of Short- Term Growth Hormone Administration¹

Franz Volhard Klinik am Max Delbrück Centrum für Molekulare Medizin, Universitätsklinikum Charité, Humboldt Universität (K.J.O., O.S., R.D.), 13125 Berlin; Lilly Deutschland GmbH (W.F.B.), 61350 Bad Homburg; and University Children’s Hospital (W.F.B.), 35392 Giessen, Germany

Address all correspondence and requests for reprints to: Dr. Karl Josef Osterziel, Franz Volhard Klinik, Wiltbergstrasse 50, 13125 Berlin, Germany. E-mail: osterziel{at}fvk-berlin.de

Treatment with human recombinant GH has yielded conflicting results in patients with heart failure. As GH sensitivity may be important for treatment effects, the present study evaluated GH secretion and sensitivity in noncachectic patients with ischemic heart failure. Twenty clinically stable, male patients with moderate heart failure (mean New York Heart Association class, 2.0 ± 0.8; mean ejection fraction, 30.0 ± 8.4%) due to coronary artery disease were randomly assigned single blind to a low dose (group A; n = 10) and a high dose (group B; n = 10) group, receiving either 5 µg/kg·day recombinant human GH for 4 days followed by 10 µg/kg·day GH for another 4 days or 10 and 20 µg/kg·day GH, respectively. Cardiac function was assessed by echocardiography. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and 24-h urinary GH excretion as a measure of pituitary GH secretion were determined at baseline and on days 5 and 9. Baseline IGF-I and IGFBP-3 levels and GH excretion were significantly diminished compared to those in age-matched controls. There was a dose-dependent increase in IGF-I and IGFBP-3 during GH treatment. The increase in IGF-I induced by 10 µg/kg·day GH correlated positively to left ventricular ejection fraction (r = 0.59; P = 0.006) and inversely to left ventricular end-diastolic and end-systolic dimensions (r < –0.6 and P < 0.01 for both). In conclusion, GH secretion and serum levels of IGF-I and IGFBP-3 are diminished in patients with moderate ischemic heart failure. Left ventricular function determines the sensitivity of the GH/IGF-I system, measured as the IGF-I response to GH application. This finding suggests that individual dose adjustments may be an indispensable prerequisite for successful GH therapy in heart failure.

This article has been cited by other articles:

				P. Le Corvoisier, L. Hittinger, P. Chanson, O. Montagne, I. Macquin-Mavier, and P. Maison Cardiac Effects of Growth Hormone Treatment in Chronic Heart Failure: A Meta-Analysis J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 180 - 185. [Abstract] [Full Text] [PDF]

				R. C. Cuneo GH and Cardiac Failure J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4635 - 4637. [Full Text] [PDF]

				J. W. A. Smit, Y. J. H. Janssen, H. J. Lamb, E. E. van der Wall, M. P. M. Stokkel, E. Viergever, N. R. Biermasz, J. J. Bax, H. W. Vliegen, A. de Roos, et al. Six Months of Recombinant Human GH Therapy in Patients with Ischemic Cardiac Failure Does Not Influence Left Ventricular Function and Mass J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4638 - 4643. [Abstract] [Full Text] [PDF]

				P. H. Wang Roads to Survival : Insulin-Like Growth Factor-1 Signaling Pathways in Cardiac Muscle Circ. Res., March 30, 2001; 88(6): 552 - 554. [Full Text] [PDF]

				K. Yamashita, J. Kajstura, D. J. Discher, B. J. Wasserlauf, N. H. Bishopric, P. Anversa, and K. A. Webster Reperfusion-Activated Akt Kinase Prevents Apoptosis in Transgenic Mouse Hearts Overexpressing Insulin-Like Growth Factor-1 Circ. Res., March 30, 2001; 88(6): 609 - 614. [Abstract] [Full Text] [PDF]